Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Liquid Biopsy Gains FDA Approval to Guide Breast Cancer Combination Therapy

By LabMedica International staff writers
Posted on 18 Nov 2026

Estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer accounts for approximately 70% of cases. More...

Acquired ESR1 mutations can cause resistance to endocrine therapies, particularly after cyclin-dependent kinase inhibitor treatment, increasing the risk of progression. A newly approved liquid biopsy companion diagnostic helps identify patients with ESR1-mutated advanced breast cancer who may benefit from an estrogen receptor antagonist combined with everolimus.

Foundation Medicine has received U.S. Food and Drug Administration (FDA) approval for FoundationOne Liquid CDx as a companion diagnostic for Wilserdly (giredestrant) in combination with everolimus. The liquid biopsy test is the first FDA-approved companion diagnostic to identify patients eligible for this combination and is covered by Medicare for patients with advanced cancer.

Wilserdly, in combination with everolimus, is indicated for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated locally advanced or metastatic breast cancer following recurrence during or after endocrine-based adjuvant therapy, or progression on at least one endocrine-based treatment in the metastatic setting.

FoundationOne Liquid CDx is an FDA-approved, next-generation sequencing (NGS)-based in vitro diagnostic test that analyzes circulating cell-free DNA from patients with advanced solid tumors. The assay profiles 324 genes and is approved to report short variants in 311 genes, rearrangements in eight genes, and copy number alterations in three genes. It also serves as a companion diagnostic for identifying patients who may benefit from specific targeted therapies in accordance with FDA-approved drug labeling.

With this latest approval, Foundation Medicine now has nine FDA-approved companion diagnostic indications in breast cancer and more than 100 indications overall. The company offers both tissue- and liquid-based comprehensive genomic profiling tests to support precision oncology. Although the assays may report additional genomic findings, these results are not necessarily predictive of response to specific therapies, and testing does not guarantee that a patient will be matched to an approved treatment.

Importantly, a negative FoundationOne Liquid CDx result does not exclude the presence of a clinically relevant alteration. Patients testing negative for companion diagnostic mutations should undergo confirmatory tumor tissue testing using an FDA-approved assay when feasible. For certain approved indications involving Rozlytrek or Tepmetko, plasma-based testing is recommended only when tumor tissue is unavailable.

“Breast cancer can mutate and become resistant to early treatments, making biomarker testing at recurrence critical,” said Vera Grossmann, interim chief executive officer and chief operating officer at Foundation Medicine. “FoundationOne Liquid CDx has the sensitivity necessary to detect ESR1, helping identify patients who may benefit the most from Genentech’s next-generation SERD combination therapy.”

Related Links
Foundation Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Drug Testing Assays
Atellica DT 250 Analyzer
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Led by Professor Sherry Chan Kit-wa (middle), the HKUMed research team provides the first large-scale Chinese population evidence to support reviewing Hong Kong’s long-term blood-monitoring requirements for clozapine use. (Photo courtesy of HKUMed)

Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine

Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.